The patient’s information shall be recorded in a standardized case-taking proforma used in NIH, Kolkata (Appendix). Following preliminary screening for insomnia and detailed screening using the specified inclusion and exclusion criteria of the screening proforma (Appendix), eligible patients will be included in the study, followed by recording of baseline scoring data. All eligible patients presenting with insomnia will be prospectively evaluated for the presence of the four characteristic symptoms of Carcinosin, as identified from the Homoeopathic Materia Medica and verified by repertorisation (Appendix). The presence or absence of these characteristic symptoms in each case will be documented systematically. If the patient’s symptom totality shows similarity with Carcinosin and the characteristic symptoms are present, Carcinosin will be prescribed as the indicated remedy. If sufficient similarity is not found, other homoeopathic medicines will be prescribed according to individual indications. The final selection of the medicine will be based on detailed case taking in adherence with standard homoeopathic guidelines - including analysis and evaluation of symptoms, miasmatic diagnosis, framing of symptom totality, and final conclusion with reference to Homoeopathic Materia Medica (Appendix). Individualized dose and potency will be selected based on the susceptibility of the patient. Subsequent prescriptions will be generated in accordance with Kent’s observations on the second prescription and other relevant homoeopathic principles, and will be recorded in follow-up sheets (Appendix). The scoring data will be re-evaluated after 6 months of treatment. Based on the presence or absence of the four characteristic symptoms and the corresponding treatment outcomes, a 2×2 contingency table will be constructed to calculate the Likelihood Ratio (LR) for each characteristic symptom of Carcinosin in insomnia cases, thereby determining its prognostic value in remedy selection.